secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001628280-25-036999
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M
--------------------------------------------------------------------------

- Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.
- Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.
- NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.
- DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.
- Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/0001628280-25-036999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/cort-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer